← Back to All Filings
Neurocrine Biosciences Officer Files Form 144 for $736K Share Sale Under Rule 10b5-1
NEUROCRINE BIOSCIENCES INC
$NBIX144CIK: 0000914475
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Form 144 Notice of Proposed Sale of Securities Issuer: NEUROCRINE BIOSCIENCES INC Filer: David Warren Boyer (Officer) Proposed Sale Amount: 4,714 shares ($736,421.08) Approx. Sale Date: 09/14/2026 Broker: Morgan Stanley Smith Barney LLC Plan Adoption Date: 02/23/2026 (Rule 10b5-1 Plan)
Comprehensive Analysis
Transaction Summary
- Insider: David Warren Boyer, Officer
- Issuer: Neurocrine Biosciences, Inc. (CIK: 0000914475)
- Filing Date: September 14, 2026
- Security: Common Stock
- Proposed Sale Size: 4,714 shares
- Aggregate Market Value: $736,421.08 (approx. $156.22 per share)
- Shares Outstanding: 101,649,181 shares
Origin and Trading Plan
- Nature of Acquisition: The securities to be sold were acquired (or are to be acquired) through the vesting of Restricted and Performance Stock Units between January 31, 2026, and September 14, 2026.
- Pre-Arranged Trading Plan: This sale is being executed pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026.
Market Significance
- Significance Level: Low
- Context: The proposed sale represents a negligible fraction of the issuer's total outstanding shares (<0.005%) and is executed under a pre-scheduled Rule 10b5-1 trading plan following equity award vesting. There were no other reported sales by the insider in the past three months.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.